A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of an adjuvanted HIV-1 Gag-Pol-Nef fusion protein and adenovirus 35 Gag-RT-Int-Nef vaccine in healthy HIV-uninfected African adults

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Omosa Manyonyi, Gloria ^a   Mpendo, Juliet ^b   Ruzagira, Eugene ^b   Kilembe, William ^c   Chomba, Elwyn ^d   Roman, François ^e   Bourguignon, Patricia ^e   Koutsoukos, Marguerite ^e   Collard, Alix ^e   Voss, Gerald ^e   Laufer, Dagna ^f   Stevens, Gwynn ^g   Hayes, Peter ^h   Clark, Lorna ^h   Cormier, Emmanuel ^h   Dally, Len ⁱ   Barin, Burc ⁱ   Ackland, Jim ^j   Syvertsen, Kristen ^f   Zachariah, Devika ^f   Anas, Kamaal ^f   Sayeed, Eddy ^f   Lombardo, Angela ^f   Gilmour, Jill ^h   Cox, Josephine ^h   Fast, Patricia ^f   Priddy, Frances ^f   more..

^a UNIVERSITY OF NAIROBI   (Kenya)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY TEACHING HOSPITAL   (Zambia)

^e GSK   (Belgium)

^f INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^g IAVI   (South Africa)

^h IAVI Core Laboratory   (United Kingdom)

ⁱ EMMES CORPORATION   (United States)

^j Global BioSolutions   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AS01B; GAG POL NEF FUSION PROTEIN; GAG REVERSE TRANSCRIPTASE INTEGRASE NEF FUSION PROTEIN; GAG RT INT NEF FUSION PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; VIRUS ANTIBODY;

ADJUVANT THERAPY; ADULT; AFRICAN; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; KENYA; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UGANDA; VIRUS INHIBITION; ZAMBIA; ADENOVIRIDAE; ADOLESCENT; BIOSYNTHESIS; BLACK PERSON; BLOOD; CELLULAR IMMUNITY; CLINICAL TRIAL; GENE VECTOR; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE SUBPOPULATION; VACCINATION; YOUNG ADULT;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; GENETIC VECTORS; HEALTHY VOLUNTEERS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; MALE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; VACCINATION; YOUNG ADULT;

EID: 84930624075     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125954     Document Type: Article

References (61)

1. McDermott AB, Koup RA. CD8(+) T cells in preventing HIV infection and disease. AIDS. 2012; 26 (10):1281-92. Epub 2012/03/24. doi: 10.1097/QAD.0b013e328353bcaf PMID: 22441256.
2. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994; 68(7):4650-5. PMID: 8207839; PubMed Central PMCID: PMC236393.
3. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(16):6776-81. doi: 10.1073/pnas.0611244104 PMID: 17428922; PubMed Central PMCID: PMC1851664.
4. Saez-Cirion A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol. 2009; 182(12):7828-37. doi: 10.4049/jimmunol.0803928 PMID: 19494307.
5. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999; 283(5403):857-60. PMID: 9933172.
6. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011; 473(7348):523-7. Epub 2011/05/13. doi: 10.1038/nature10003 PMID: 21562493; PubMed Central PMCID: PMC3102768.
7. Van Braeckel E, Bourguignon P, Koutsoukos M, Clement F, Janssens M, Carletti I, et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2011; 52(4):522-31. Epub 2011/01/07. doi: 10.1093/cid/ciq160 PMID: 21208909; PubMed Central PMCID: PMC3060898.
8. Van Braeckel E, Desombere I, Clement F, Vandekerckhove L, Verhofstede C, Vogelaers D, et al. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. Vaccine. 2013; 31(36):3739-46. Epub 2013/05/28. doi: 10.1016/j.vaccine.2013.05.021 PMID: 23707169.
9. Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012; 7(8):e41936. doi: 10.1371/journal.pone.0041936 PMID: 22870265; PubMed Central PMCID: PMC3411704.
10. Baden LR, Liu J, Li H, Johnson JA, Walsh SR, Kleinjan JA, et al. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. The Journal of infectious diseases. 2015; 211(4):518-28. Epub 2014/08/29. doi: 10.1093/infdis/jiu485 PMID: 25165165; PubMed Central PMCID: PMC4318919.
11. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. The Journal of infectious diseases. 2006; 194(12):1650-60. doi: 10.1086/509259 PMID: 17109336; PubMed Central PMCID: PMC2428069.
12. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2008; 46 (11):1769-81. doi: 10.1086/587993 PMID: 18433307.
13. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012; 482(7383):89-93. Epub 2012/01/06. doi: 10.1038/nature10766 PMID: 22217938; PubMed Central PMCID: PMC3271177.
14. Bart PA, Huang Y, Karuna ST, Chappuis S, Gaillard J, Kochar N, et al. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. J Clin Invest. 2014; 124(11):4843-56. Epub 2014/10/02. doi: 10.1172/JCI75894 PMID: 25271627; PubMed Central PMCID: PMC4347219.
15. Sarzotti-Kelsoe M, Cox J, Cleland N, Denny T, Hural J, Needham L, et al. Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials. PLoS Med. 2009; 6(5): e1000067. doi: 10.1371/journal.pmed.1000067 PMID: 19536325; PubMed Central PMCID: PMC2670502.
16. Stiles T, Grant V, Mawbey T. Good Clinical Laboratory Practice (GCLP). A quality sytem for laboratories that undertake the analysis of samples from clinical trials. Assurance BAoRQ, editor: BARQA ISBN 978-1-904610-00-7; 2010. 1-17 p.
17. Boaz MJ, Hayes P, Tarragona T, Seamons L, Cooper A, Birungi J, et al. Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clinical and vaccine immunology: CVI. 2009; 16(2):147-55. doi: 10.1128/CVI.00326-08 PMID: 19091991; PubMed Central PMCID: PMC2643552.
18. Gill DK, Huang Y, Levine GL, Sambor A, Carter DK, Sato A, et al. Equivalence of ELISpot Assays Demonstrated between Major HIV Network Laboratories. PLoS ONE. 2010; 5(12):e14330. doi: 10.1371/journal.pone.0014330 PMID: 21179404
19. Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, et al. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. The Journal of infectious diseases. 2010; 201(5):720-9. doi: 10.1086/650492 PMID: 20132004.
20. Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003; 41(11):5046-52. doi: 10.1128/jcm.41.11.5046-5052.2003 PMID: 14605137; PubMed Central PMCID: PMC262545.
21. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, et al. A Blueprint for HIV Vaccine Discovery. Cell host & microbe. 2012; 12(4):396-407. Epub 2012/10/23. doi: 10.1016/j.chom.2012.09.008 PMID: 23084910; PubMed Central PMCID: PMC3513329.
22. Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, et al. Accelerating next-generation vaccine development for global disease prevention. Science. 2013; 340(6136):1232910. Epub 2013/06/01. doi: 10.1126/science.1232910 PMID: 23723240; PubMed Central PMCID: PMC4026248.
23. Koup RA, Graham BS, Douek DC. The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol. 2011; 11(1):65-70. Epub 2010/12/18. doi: 10.1038/nri2890 PMID: 21164527.
24. Makedonas G, Betts MR. Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev. 2011; 239(1):109-24. Epub 2011/01/05. doi: 10.1111/j.1600-065X.2010.00968.x PMID: 21198668; PubMed Central PMCID: PMC3025661.
25. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. 2010; 33(4):542-54. doi: 10.1016/j.immuni.2010.09.011 PMID: 21029964; PubMed Central PMCID: PMC3031162.
26. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008; 372(9653):1881-93. doi: 10.1016/S0140-6736(08)61591-3 PMID: 19012954; PubMed Central PMCID: PMC2721012.
27. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011; 11(7):507-15. Epub 2011/05/17. doi: 10.1016/S1473-3099(11)70098-6 PMID: 21570355; PubMed Central PMCID: PMC3417349.
28. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013; 369(22):2083-92. doi: 10.1056/NEJMoa1310566 PMID: 24099601; PubMed Central PMCID: PMC4030634.
29. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008; 372(9653):1894-905. doi: 10.1016/S0140-6736(08)61592-5 PMID: 19012957; PubMed Central PMCID: PMC2774110.
30. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361(23):2209-20. doi: 10.1056/NEJMoa0908492 PMID: 19843557.
31. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol. 2012; 188(10):5166-76. Epub 2012/04/25. doi: 10.4049/jimmunol.1102756 PMID: 22529301; PubMed Central PMCID: PMC3383859.
32. Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, et al. MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. PLoS One. 2012; 7(8):e43396. Epub 2012/09/07. doi: 10.1371/journal.pone.0043396 PMID: 22952672; PubMed Central PMCID: PMC3428369.
33. Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, Cole S, et al. Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One. 2011; 6(6):e20479. Epub 2011/06/23. doi: 10.1371/journal.pone.0020479 PMID: 21695251; PubMed Central PMCID: PMC3112144.
34. Rolland M, Tovanabutra S, deCamp AC, Frahm N, Gilbert PB, Sanders-Buell E, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med. 2011; 17(3):366-71. Epub 2011/03/02. doi: 10.1038/nm.2316 PMID: 21358627; PubMed Central PMCID: PMC3053571.
35. Chevalier MF, Julg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, et al. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol. 2011; 85(2):733-41. Epub 2010/11/05. doi: 10.1128/JVI.02030-10 PMID: 21047960; PubMed Central PMCID: PMC3020027.
36. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997; 278(5342):1447-50. PMID: 9367954.
37. Streeck H, D'Souza MP, Littman DR, Crotty S. Harnessing CD4(+) T cell responses in HIV vaccine development. Nat Med. 2013; 19(2):143-9. Epub 2013/02/08. doi: 10.1038/nm.3054 PMID: 23389614; PubMed Central PMCID: PMC3626561.
38. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One. 2011; 6(8):e21225. doi: 10.1371/journal.pone.0021225 PMID: 21857901; PubMed Central PMCID: PMC3152265.
39. Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, et al. Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa. PLoS ONE. 2010; 5(9):e12873. doi: 10.1371/journal.pone.0012873 PMID: 20877623
40. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, et al. A Phase I/II Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus-type 5 Boost Vaccine in HIV Uninfected East Africans (RV 172). The Journal of infectious diseases. 2010; 201(4):600-7. doi: 10.1086/650299 PMID: 20078213
41. Chattopadhyay PK, Yu J, Roederer M. Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression. Nat Protoc. 2006; 1(1):1-6. Epub 2007/04/05. doi: 10.1038/nprot.2006.1 PMID: 17406204.
42. Frentsch M, Arbach O, Kirchhoff D, Moewes B, Worm M, Rothe M, et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med. 2005; 11(10):1118-24. Epub 2005/09/28. doi: 10.1038/nm1292 PMID: 16186818.
43. Samten B, Thomas EK, Gong J, Barnes PF. Depressed CD40 ligand expression contributes to reduced gamma interferon production in human tuberculosis. Infection and immunity. 2000; 68(5):3002-6. Epub 2000/04/18. PMID: 10769003; PubMed Central PMCID: PMC97518.
44. Stubbe M, Vanderheyde N, Goldman M, Marchant A. Antigen-specific central memory CD4+ T lymphocytes produce multiple cytokines and proliferate in vivo in humans. J Immunol. 2006; 177(11):8185-90. Epub 2006/11/23. PMID: 17114495.
45. Harrer T, Plettenberg A, Arasteh K, Van Lunzen J, Fatkenheuer G, Jaeger H, et al. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study. Vaccine. 2014; 32(22):2657-65. Epub 2013/10/23. doi: 10.1016/j.vaccine.2013.10.030 PMID: 24144472.
46. Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, Overman RG, et al. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol. 2010; 84(10):4998-5006. doi: 10.1128/JVI.00138-10 PMID: 20200250; PubMed Central PMCID: PMC2863846.
47. Freel SA, Picking RA, Ferrari G, Ding H, Ochsenbauer C, Kappes JC, et al. Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J Virol. 2012; 86 (12):6835-46. Epub 2012/04/20. doi: 10.1128/JVI.00437-12 PMID: 22514337; PubMed Central PMCID: PMC3393529.
48. Yang H, Wu H, Hancock G, Clutton G, Sande N, Xu X, et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. The Journal of infectious diseases. 2012; 206(4):552-61. Epub 2012/06/20. doi: 10.1093/infdis/jis379 PMID: 22711904; PubMed Central PMCID: PMC4192045.
49. Kopycinski J, Hayes P, Ashraf A, Cheeseman H, Lala F, Czyzewska-Khan J, et al. Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2014; 9(3):e90378. Epub 2014/03/13. doi: 10.1371/journal.pone.0090378 PMID: 24609066; PubMed Central PMCID: PMC3946500.
50. Leroux-Roels I, Koutsoukos M, Clement F, Steyaert S, Janssens M, Bourguignon P, et al. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine. 2010; 28(43):7016-24. Epub 2010/08/24. doi: 10.1016/j.vaccine.2010.08.035 PMID: 20728522.
51. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011; 29 (32):5203-9. Epub 2011/05/31. doi: 10.1016/j.vaccine.2011.05.025 PMID: 21619905; PubMed Central PMCID: PMC3138857.
52. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS. 2004; 18 (8):1213-6. Epub 2004/05/29. 00002030-200405210-00019 [pii]. PMID: 15166541.
53. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003; 77(15):8263-71. doi: 10.1128/jvi.77.15.8263-8271.2003 PMID: 12857895; PubMed Central PMCID: PMC165227.
54. Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther. 2014; 22(3):668-74. Epub 2014/01/01. doi: 10.1038/mt.2013.284 PMID: 24374965; PubMed Central PMCID: PMC3944330.
55. Ouedraogo A, Tiono AB, Kargougou D, Yaro JB, Ouedraogo E, Kabore Y, et al. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS One. 2013; 8(11):e78679. Epub 2013/11/19. doi: 10.1371/journal.pone.0078679 PMID: 24244339; PubMed Central PMCID: PMC3823848.
56. Penaloza-MacMaster P, Provine NM, Ra J, Borducchi EN, McNally A, Simmons NL, et al. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol. 2013; 87(3):1373-84. Epub 2012/11/16. doi: 10.1128/JVI.02058-12 PMID: 23152535; PubMed Central PMCID: PMC3554181.
57. Creech CB, Dekker CL, Ho D, Phillips S, Mackey S, Murray-Krezan C, et al. Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults. Human vaccines & immunotherapeutics. 2013; 9(12):2548-57. Epub 2013/08/21. doi: 10.4161/hv.26038 PMID: 23955431; PubMed Central PMCID: PMC4162066.
58. Fauci AS, Marovich MA, Dieffenbach CW, Hunter E, Buchbinder SP. Immunology. Immune activation with HIV vaccines. Science. 2014; 344(6179):49-51. Epub 2014/04/05. doi: 10.1126/science.1250672 PMID: 24700849.
59. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest. 2012; 122(1):359-67. Epub 2011/12/29. doi: 10.1172/JCI60202 PMID: 22201684; PubMed Central PMCID: PMC3248307.
60. Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(50):E3503-12. doi: 10.1073/pnas.1208972109 PMID: 23151505; PubMed Central PMCID: PMC3528489.
61. Huang Y, Karuna ST, Janes H, Frahm N, Nason M, Edlefsen PT, et al. Use of placebos in Phase 1 preventive HIV vaccine clinical trials. Vaccine. 2015; 33(6):749-52. doi: 10.1016/j.vaccine.2014.10.017 PMID: 25454855.